# | Title | Journal | Year | Citations |
---|
|
1 | First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer | New England Journal of Medicine | 2014 | 2,886 |
2 | Genome-wide association study identifies novel breast cancer susceptibility loci | Nature | 2007 | 2,179 |
3 | Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers | JAMA - Journal of the American Medical Association | 2017 | 2,039 |
4 | Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK | Journal of Clinical Oncology | 2009 | 1,792 |
5 | Comprehensive genomic profiles of small cell lung cancer | Nature | 2015 | 1,744 |
6 | Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer | New England Journal of Medicine | 2014 | 1,710 |
7 | Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial | Lancet, The | 2004 | 1,576 |
8 | Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders | Nature Reviews Drug Discovery | 2014 | 1,312 |
9 | Whole–genome characterization of chemoresistant ovarian cancer | Nature | 2015 | 1,263 |
10 | Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study | Lancet, The | 2020 | 1,237 |
11 | Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer | Nature Genetics | 2012 | 1,216 |
12 | PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma | New England Journal of Medicine | 2018 | 1,072 |
13 | Translational biology of osteosarcoma | Nature Reviews Cancer | 2014 | 1,000 |
14 | Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry | Annals of Oncology | 2019 | 925 |
15 | Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer | New England Journal of Medicine | 2020 | 877 |
16 | [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study | Lancet Oncology, The | 2018 | 872 |
17 | Cervical cancer: A global health crisis | Cancer | 2017 | 858 |
18 | 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) | Annals of Oncology | 2020 | 854 |
19 | Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients | Oncotarget | 2016 | 842 |
20 | A comparison of background correction methods for two-colour microarrays | Bioinformatics | 2007 | 833 |
21 | Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project | Blood | 2009 | 832 |
22 | Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer | Science Translational Medicine | 2010 | 763 |
23 | Randomized Trial of Short-Course Radiotherapy Versus Long-Course Chemoradiation Comparing Rates of Local Recurrence in Patients With T3 Rectal Cancer: Trans-Tasman Radiation Oncology Group Trial 01.04 | Journal of Clinical Oncology | 2012 | 759 |
24 | Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor–Positive Breast Carcinomas Through Genomic Grade | Journal of Clinical Oncology | 2007 | 722 |
25 | Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia | New England Journal of Medicine | 2018 | 722 |
26 | Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02 | Journal of Clinical Oncology | 2010 | 698 |
27 | Prognostic Significance of p16INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial | Journal of Clinical Oncology | 2010 | 685 |
28 | Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer—Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis | European Urology | 2020 | 658 |
29 | Lymphangiogenesis and lymphatic vessel remodelling in cancer | Nature Reviews Cancer | 2014 | 650 |
30 | Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary | Journal of Pathology | 2010 | 635 |
31 | [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial | Lancet, The | 2021 | 629 |
32 | Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells | Clinical Cancer Research | 2013 | 612 |
33 | Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors | Advances in Anatomic Pathology | 2017 | 576 |
34 | Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases | Journal of Clinical Oncology | 2015 | 563 |
35 | Does Lung Adenocarcinoma Subtype Predict Patient Survival?: A Clinicopathologic Study Based on the New International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Lung Adenocarcinoma Classification | Journal of Thoracic Oncology | 2011 | 556 |
36 | Prognostic Significance of [18F]-Misonidazole Positron Emission Tomography–Detected Tumor Hypoxia in Patients With Advanced Head and Neck Cancer Randomly Assigned to Chemoradiation With or Without Tirapazamine: A Substudy of Trans-Tasman Radiation Oncology Group Study 98.02 | Journal of Clinical Oncology | 2006 | 533 |
37 | Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline | Practical Radiation Oncology | 2012 | 525 |
38 | Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma | Leukemia | 2010 | 522 |
39 | The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant | Cancer Treatment Reviews | 2015 | 501 |
40 | Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research | Advances in Anatomic Pathology | 2017 | 501 |
41 | Radiotherapy toxicity | Nature Reviews Disease Primers | 2019 | 497 |
42 | A Microenvironment-Induced Myeloproliferative Syndrome Caused by Retinoic Acid Receptor γ Deficiency | Cell | 2007 | 496 |
43 | Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germlineCDH1mutation carriers | Journal of Medical Genetics | 2015 | 488 |
44 | Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions | Journal of Clinical Oncology | 2007 | 478 |
45 | Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer | New England Journal of Medicine | 2018 | 475 |
46 | Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape | European Journal of Cancer | 2017 | 465 |
47 | Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial | Lancet, The | 2017 | 461 |
48 | Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy | Journal of Clinical Oncology | 2020 | 459 |
49 | Consensus guidelines for the use and interpretation of angiogenesis assays | Angiogenesis | 2018 | 457 |
50 | Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor | Journal of Clinical Oncology | 2013 | 449 |